BioLife Solutions, Inc. $BLFS Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA reduced its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 8.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,004,164 shares of the medical equipment provider’s stock after selling 93,188 shares during the period. Massachusetts Financial Services Co. MA’s holdings in BioLife Solutions were worth $24,281,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Capricorn Fund Managers Ltd purchased a new position in shares of BioLife Solutions in the fourth quarter valued at approximately $9,153,000. SG Americas Securities LLC lifted its position in shares of BioLife Solutions by 137.3% in the fourth quarter. SG Americas Securities LLC now owns 27,128 shares of the medical equipment provider’s stock valued at $656,000 after acquiring an additional 15,697 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of BioLife Solutions by 85.2% in the third quarter. Tudor Investment Corp ET AL now owns 111,356 shares of the medical equipment provider’s stock valued at $2,841,000 after acquiring an additional 51,217 shares in the last quarter. Connors Investor Services Inc. purchased a new position in shares of BioLife Solutions in the third quarter valued at approximately $224,000. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of BioLife Solutions in the third quarter valued at approximately $1,064,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Buying and Selling

In related news, insider Karen A. Foster sold 96,923 shares of BioLife Solutions stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the transaction, the insider owned 113,742 shares in the company, valued at approximately $2,291,901.30. This trade represents a 46.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 99,641 shares of company stock worth $2,009,000 in the last quarter. Company insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Northland Securities set a $34.00 target price on BioLife Solutions in a research report on Monday, January 5th. UBS Group restated a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Wall Street Zen upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $21.19 on Thursday. BioLife Solutions, Inc. has a one year low of $17.86 and a one year high of $29.62. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -192.62 and a beta of 2.00. The business’s 50 day moving average price is $20.61 and its 200 day moving average price is $23.87.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.